Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.
about
A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challengeInduction of protective immunity against Chlamydia muridarum intravaginal infection with a chlamydial glycogen phosphorylaseAntibodies from women urogenitally infected with C. trachomatis predominantly recognized the plasmid protein pgp3 in a conformation-dependent mannerCationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.Chlamydial protease-like activity factor--insights into immunity and vaccine developmentA MyD88-dependent early IL-17 production protects mice against airway infection with the obligate intracellular pathogen Chlamydia muridarum.Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infectionChlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positiveLack of long-lasting hydrosalpinx in A/J mice correlates with rapid but transient chlamydial ascension and neutrophil recruitment in the oviduct following intravaginal inoculation with Chlamydia muridarum.Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques.Complement factor C5 but not C3 contributes significantly to hydrosalpinx development in mice infected with Chlamydia muridarum.Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection.Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigenIdentification of immunodominant antigens by probing a whole Chlamydia trachomatis open reading frame proteome microarray using sera from immunized mice.Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarraysVaccination against Chlamydia genital infection utilizing the murine C. muridarum model.Antibody signature of spontaneous clearance of Chlamydia trachomatis ocular infection and partial resistance against re-challenge in a nonhuman primate trachoma model.Intranasal vaccination with Chlamydia pneumoniae induces cross-species immunity against genital Chlamydia muridarum challenge in mice.Immunogenicity of a vaccine formulated with the Chlamydia trachomatis serovar F, native major outer membrane protein in a nonhuman primate modelOviduct infection and hydrosalpinx in DBA1/j mice is induced by intracervical but not intravaginal inoculation with Chlamydia muridarum.The hypothetical protein CT813 is localized in the Chlamydia trachomatis inclusion membrane and is immunogenic in women urogenitally infected with C. trachomatis.A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.Management of Chlamydia trachomatis genital tract infection: screening and treatment challenges.Amphipols stabilize the Chlamydia major outer membrane protein and enhance its protective ability as a vaccineApproach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccinesInduction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.TRAIL-R1 is a negative regulator of pro-inflammatory responses and modulates long-term sequelae resulting from Chlamydia trachomatis infections in humans.Pathogenesis of genital tract disease due to Chlamydia trachomatisA TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors.Association of tubal factor infertility with elevated antibodies to Chlamydia trachomatis caseinolytic protease P.Chlamydia muridarum induction of glandular duct dilation in mice.Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.Characterization of Francisella tularensis outer membrane proteins.Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.Porin activity of Anaplasma phagocytophilum outer membrane fraction and purified P44.The protective efficacy of chlamydial protease-like activity factor vaccination is dependent upon CD4+ T cells
P2860
Q28391567-872BA974-6869-487A-B868-725AF3C40692Q28731379-AA072337-7B07-48E4-A5ED-36F2831A593AQ33341501-8A55CD52-C894-4CE8-A682-46200C4EAD30Q33367582-EA1E9D60-C6F4-42DC-A842-BC85F9CAC606Q33584064-E64AA67A-553B-410F-96F4-BB2AAB830C13Q33606828-297BF0E6-E63C-4A46-ABC6-E8A8FE25E9D7Q33648677-A5E6B4A9-D793-415C-9514-D381C145BFE9Q33653334-77B22F80-4DF8-464A-878E-1F490CC96192Q33826107-1C0FA323-5DDF-4B5B-9AC5-B023290B5A5CQ33899705-9D2E661E-7E1F-4A6D-837F-DCA35D7C26E6Q33957971-4876E6E0-5EEB-4CC2-8287-1425B3625BF2Q34059023-C20389D9-B193-4431-A372-E328ACCE7F42Q34103785-2569337D-E4E7-42DB-80C5-A6683E95C7F6Q34119450-DD26A140-872B-4CDA-B997-3012F7E685C8Q34177368-FAAC018A-B6DA-4F02-A60A-CCDE7D604C13Q34311438-BAE645EF-E75B-4508-91F6-9C35CEDD1BDCQ34478609-BCDEA90B-7934-48A7-AC05-2012FADB7A75Q34484641-FC5B5AB5-DF0B-45F0-8AC3-8E722494CC07Q34623193-4CB24688-997F-46A5-8CF0-5F38CA8CBEF4Q34739969-27CD29B8-BBD7-4248-8387-899104EE4E32Q34759137-8AC0458B-0E4B-475B-864A-6E69EFB8ACD6Q34760989-B39F143B-D82E-4996-ABE5-E59EC2036581Q34886221-B5DE5E8B-33BE-45FA-9C01-241092442EF0Q34937975-918DAB83-056A-41CD-BB9F-3E76951D4DCDQ34975886-D1985E0F-F5F2-4532-B18B-51625E38C7CFQ34980175-C4150C78-75FA-447F-8A36-BBAFA56DD119Q35026625-4E82BDAF-317F-40FA-8AD7-C97A6532251AQ35042764-AF28EFF2-CF38-4AFB-8538-8FF8FCB233E6Q35049146-D1D7FF8F-525B-43F0-B273-7F0041362662Q35113308-E2296A32-7189-48C5-9B15-2C2149D8F08AQ35138611-7DF0546B-24E0-43F4-9BED-7845333A14C4Q35148159-24D6FA7E-D533-40FE-9BB5-E915275D9499Q35166960-C52294DB-B5BC-46D4-9CDF-2274063BEC2CQ35570151-DEC8A97D-AF1B-492B-A3D2-62CAE957235EQ35609279-DF421CD7-8008-4322-9852-B52E56F17630Q35634194-BCD7F1B3-D2BC-46FE-8491-2AEEC1FF8D54Q35634834-D60D815A-A292-4651-82C3-281EF7769DD0Q35689196-5A7EE50C-0FF6-4703-A643-23402B03FE16Q35759413-78C3AE23-D478-4B1E-A1A5-F1B8F815D816Q35828850-98C44631-FC51-4397-81AA-732A3817A413
P2860
Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Vaccination with the Chlamydia ...... noculation with live bacteria.
@ast
Vaccination with the Chlamydia ...... noculation with live bacteria.
@en
Vaccination with the Chlamydia ...... noculation with live bacteria.
@nl
type
label
Vaccination with the Chlamydia ...... noculation with live bacteria.
@ast
Vaccination with the Chlamydia ...... noculation with live bacteria.
@en
Vaccination with the Chlamydia ...... noculation with live bacteria.
@nl
prefLabel
Vaccination with the Chlamydia ...... noculation with live bacteria.
@ast
Vaccination with the Chlamydia ...... noculation with live bacteria.
@en
Vaccination with the Chlamydia ...... noculation with live bacteria.
@nl
P2093
P2860
P1476
Vaccination with the Chlamydia ...... noculation with live bacteria.
@en
P2093
Ellena M Peterson
Luis M de la Maza
Sukumar Pal
P2860
P304
P356
10.1128/IAI.73.12.8153-8160.2005
P407
P577
2005-12-01T00:00:00Z